Table 2.
Effect of Combination Therapy with HBIG and Lamivudine to Prevent HBV Reinfection After OLT. (IV, intravenous; IM, intramuscular, NR, not reported.)
| Authors | N= | Pre-OLT Duration* of LAM(mos) | HBV DNANegative at OLT(%) | HBIGRoute of Administration | HBV Reinfection(%) | Reference |
|---|---|---|---|---|---|---|
| Markowitz, et al. | 14 | 3 | 93 | IV | 0 | 43 |
| Yao, et al. | 10 | 8.6 | 80 | IV then IM | 10 | 75 |
| Yoshida, et al. | 7 | NR | 100 | IM | 0 | 80 |
| Angus, et al. | 37 | 3.2 | NR | IM | 3 | 18 |
| Marzano, et al. | 33 | 4.6 | 100 | IV | 4 | 15 |
| McCaughan, et al. | 9 | 0 | NR | IM | 0 | 81 |
| Rosenau, et al. | 21 | 4.6 | 77 | IV | 10 | 49 |
| Roche, et al. | 15 | 4.6 | 73 | IV | 7 | 28 |
| Han, et al. | 59 | NR | NR | IV | 0 | 14 |
| Seehofer, et al. | 17 | 10.6 | 71 | IV | 18 | 48 |